Winship Cancer Institute of Emory University was awarded a P01 program project grant from NCI to support research aimed at improving the effectiveness of immunotherapy for lung cancer in patients with a mutation of the LKB1 gene, a group for whom present immunotherapy options do not provide robust benefit.
More than half of deaths that are not attributed to disease progression or recurrence after CAR T-cell therapy are caused by infections—an unprecedented finding that experts say marks a shift from a conventional focus on mitigating treatment-specific adverse events to including prevention and management of infections.
